Business Daily Media

Men's Weekly

.

Zuellig Pharma and Institut AllergoSan sign 10-year regional partnership to bring leading probiotic brand OMNi-BiOTiC® to key markets in Asia

New agreement marks major milestone for Zuellig Pharma as it focuses on expanding its consumer healthcare segment, and for Institut AllergoSan as it expands its global presence

SINGAPORE - Media OutReach Newswire - 19 July 2024 - Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has signed a 10-year commercialisation partnership with Austria-based Institut AllergoSan, a research and development company that specialises in products made from natural substances such as probiotic bacteria, plant extracts and minerals.

Anita Frauwallner, founder and CEO of Institut AllergoSan (left) and John Graham, Group CEO, Zuellig Pharma (right) at the partnership signing ceremony to bring OMNi-BiOTiC® to key markets in Asia.
Anita Frauwallner, founder and CEO of Institut AllergoSan (left) and John Graham, Group CEO, Zuellig Pharma (right) at the partnership signing ceremony to bring OMNi-BiOTiC® to key markets in Asia.

Under this partnership, Zuellig Pharma will provide a wide spectrum of commercialisation support, including product registration, sales and marketing, and warehousing and distribution services to bring OMNi-BiOTiC®, one of Institut AllergoSan's leading probiotic brands, to key markets in Asia.

"Our consumer healthcare segment will be one of the key growth drivers in our business over the coming years and this partnership represents a significant step forward in our commitment to delivering innovative and accessible healthcare solutions to patients in Asia. With a fast-growing probiotics market in Asia, the comprehensive and tailored solutions offered through our commercialisation division, ZP Therapeutics, will help our partners expand their footprint to meet greater consumer demand for gut health products in this region. Together with Institut AllergoSan, we will leverage our combined expertise to enhance the well-being of consumers and drive forward our mission of making healthcare more accessible," said John Graham, Group CEO, Zuellig Pharma.

"We are dedicated to supporting consumers' pursuit of a healthier, more vital self and offer medically relevant probiotic supplements that target specific health needs and deliver clinically backed results. OMNi-BiOTiC® is the top selling probiotic brand in all German-speaking markets in Europe such as Austria, Germany and Switzerland[1] and we look forward to working closely with Zuellig Pharma to bring these innovative products to everybody in Asia who wants to promote an active, healthy life," adds Anita Frauwallner, founder and CEO of Institut AllergoSan.

Zuellig Pharma plans to launch OMNi-BiOTiC® in Indonesia, the Philippines and Taiwan in 2025, followed by other key markets thereafter.


[1] IQVIA OTC Global Insights 2023, 03F1/A7F, IQVIA OTC Audits / Public Price in EUR.
Hashtag: #ZuelligPharma #InstitutAllergoSan #Healthcare #Probiotics #ConsumerHealthcare #GutHealth #Commercialisation



The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

ZP Therapeutics, a division of Zuellig Pharma, is the commercialisation partner of choice for the healthcare industry with offices in 13 countries across Asia and over 2,500 associates. A catalyst in improving patient journeys and healthcare outcomes through commercial excellence, robust in-market capabilities and strong ethical principles, ZP Therapeutics is a trusted partner for expanding patient access and providing innovations to the healthcare community.

For more information, visit:

About Institut AllergoSan

Institut AllergoSan, based in Graz, Austria, was founded in 1991 by a group of integrative doctors and pharmacists together with Anita Frauwallner, who is now the managing director. Since then, the company has been focused on the scientific research and development of products made from natural substances such as probiotic bacteria, dietary fibres, micronutrients, and plant extracts. Through the intensive cooperation between Institut AllergoSan and recognised scientists from the fields of medicine, pharmacy, and biochemistry, it has been possible to build up a recognised research and competence centre focused on the largest organ of the human body - the intestine. This has resulted in the OMNi-BiOTiC®, OMNi-LOGiC® and META-CARE® product range, among others.

It has been a true pioneering spirit that drove Anita Frauwallner to embark on a largely unknown path more than 30 years ago: she has dedicated her life to microbiome research and the development of innovative, high-quality probiotics. This spirit has brought OMNi-BiOTiC® to rank today as number 3 on the global probiotic market and number 1 in German-speaking Europe and numerous other countries.

News from Asia

Trend Micro Enhances AI Safety and Security in NVIDIA Enterprise AI Factories

Trend Secure AI Factory supports NVIDIA NeMo continuous model safety evaluation and improvement lifecycle HONG KONG SAR - Media OutReach Newswire - 12 June 2025 - Trend Micro Incorporated (TYO: 4...

PolyU startups showcase innovation and entrepreneurial achievements at London Tech Week 2025

HONG KONG SAR - Media OutReach Newswire - 12 June 2025 - The Hong Kong Polytechnic University (PolyU) took part in the world-renowned London Tech Week 2025 held from 9 to 11 June in London, UK, as...

InvestHK and London ETO strengthen HKSAR-UK innovation ties at London Tech Week 2025

LONDON, UNITED KINGDOM - Media OutReach Newswire - 12 June 2025 - Invest Hong Kong (InvestHK) and the Hong Kong Economic and Trade Office, London (London ETO) are wrapping up a strong presence at ...

Arup drives global infrastructure collaboration at IIICF

HONG KONG SAR - Media OutReach Newswire - 12 June 2025 - The 16th International Infrastructure Investment and Construction Forum (IIICF), co-hosted by the Macao Commerce and Investment Promotion I...

Kind + Jugend ASEAN 2025 Kicks Off: Southeast Asia’s Premier Trade Show for Maternity, Baby & Kids Products Empowers Thai and ASEAN Businesses to Enter the Global Market

BANGKOK, THAILAND - Media OutReach Newswire - 12 June 2025 - The third edition of Kind + Jugend ASEAN 2025 officially inaugurated today at the Queen Sirikit National Convention Center, continuing ...

Galaxy Macau Celebrates Standout Industry Recognition with 20 Award Wins at Tatler Best Awards 2025 Hong Kong and Macau

MACAU SAR - Media OutReach Newswire – 12 June 2025 - Galaxy Macau™ ("Galaxy Macau") the world-class luxury resort, is proud to celebrate a total of 20 of its restaurants, bars, and hotels at Galax...

GeoTechnologies’ Move-to-earn app rapidly gained popularity in Japan has surpassed 23 million downloads worldwide

- Launch a commemorative campaign by celebrating the Japanese app "TRIMA" surpassing 22 million downloads in Japan and its US version "GeoSmile" reaching 1 million downloads - TOKYO, JAPAN - Medi...

Dongfeng Motor Launches Flagship Innovation, Driving Global Value Chain Advancement with China Intelligent Manufacturing

HONG KONG SAR - Media OutReach Newswire - 13 June 2025 - The International Automotive & Supply Chain Expo (Hong Kong) 2025 opened on June 12, bringing together global industry leaders...

Momcozy M9 Wearable Breast Pump Wins Innovation Award at Kind + Jugend ASEAN 2025

BANGKOK, THAILAND - Media OutReach Newswire - 13 June 2025 - Momcozy, a global leader in mother and baby care, proudly announced that its Mobile Flow™ Hands-Free Breast Pump (M9) has been honore...

DHL Supply Chain certified a Great Place to Work® across Asia Pacific

All countries under DHL Supply Chain APAC are now certified DHL Supply Chain Japan becomes the newest office to achieve certification SINGAPORE - Media OutReach Newswire - 13...

Technical Debt Stifling Path to AI Adoption for Global Enterprises

Outdated legacy technologies costing organisations the ability to innovate, money, time and potentially, even customers Technical debt and an ov...

Attract. Impress. Keep. The new small business growth playbook

Running a small business is a marathon that often feels like a sprint. You are chasing leads, juggling admin, building a brand and trying to carve...

Amazon to expand data centre infrastructure in Australia and strengthen AI

Amazon has announced plans to invest a new total of AU$20 billion from 2025 to 2029 to expand, operate, and maintain its data centre infrastructur...

How AI is Reshaping Banking in Australia

AI in the Banking and Financial Services Industry  From fraud detection and credit scoring to personalised financial advice, AI is transforming t...

Tracksuit set for growth after $38M investment

Tracksuit Raises $38M Series B to Accelerate Global Expansion and Boost its Growing US Presence VMG Partners leads oversubscribed round; Tracksui...

Deputy Launches Payroll in Australia: Purpose Built for Shift-Based Businesses

Deputy, the global people platform purpose-built for shift work, officially launched Deputy Payroll in Australia today — a seamless experience desig...

Sell by LayBy